Cencora, Inc. (NYSE:COR) Shares Sold by Ballentine Partners LLC

Ballentine Partners LLC lessened its position in shares of Cencora, Inc. (NYSE:COR) by 0.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,528 shares of the company’s stock after selling 81 shares during the period. Ballentine Partners LLC’s holdings in Cencora were worth $1,919,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD purchased a new position in Cencora in the first quarter valued at $2,183,619,000. JPMorgan Chase & Co. acquired a new position in shares of Cencora during the 1st quarter worth about $1,199,695,000. Boston Partners purchased a new position in shares of Cencora in the 1st quarter valued at about $1,001,269,000. Capital Research Global Investors purchased a new position in shares of Cencora in the 1st quarter valued at about $650,424,000. Finally, Bessemer Group Inc. acquired a new stake in shares of Cencora during the 1st quarter worth about $556,245,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,461,153 shares of company stock valued at $1,073,075,720 over the last ninety days. Corporate insiders own 15.80% of the company’s stock.

Cencora Stock Down 0.3 %

COR opened at $234.47 on Friday. Cencora, Inc. has a 52 week low of $182.75 and a 52 week high of $247.66. The business has a 50 day moving average price of $232.15 and a two-hundred day moving average price of $230.87. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The company has a market cap of $46.77 billion, a PE ratio of 25.65, a P/E/G ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. During the same quarter in the prior year, the business earned $2.92 earnings per share. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. As a group, research analysts anticipate that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora’s payout ratio is 22.32%.

Wall Street Analysts Forecast Growth

COR has been the topic of several recent analyst reports. Evercore ISI dropped their price target on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Robert W. Baird dropped their target price on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Wells Fargo & Company upped their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Finally, Bank of America reiterated a “neutral” rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $259.44.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.